Colossal Sues Ex-Executive Over Trade Secrets
Colossal Biosciences alleges former senior executive James Kehler took confidential information before joining a competing start-up.
Updated on Nov. 6, 2026 in Biotech
Colossal Biosciences has sued former senior executive James Kehler in US federal court in Texas, alleging he used his company laptop to transfer confidential and trade secret information to personal accounts and devices before leaving. Kehler joined Neion Bio, a start-up manufacturing medicines in chicken eggs, in April 2026, and did not immediately respond to a request for comment.
Why it matters
Colossal alleges the knowhow behind its de-extinction project and Neion's manufacturing processes are the same, a claim that puts the boundaries of trade secrets in the fast-growing biotech sector under scrutiny. The case highlights how talent movement between competing ventures can raise intellectual property disputes.
The lawsuit is based on Colossal's allegations rather than adjudicated findings, and the company's claim that its de-extinction knowhow and Neion's manufacturing processes are the same has not been independently verified. Colossal, valued at $10.2bn in January 2025, is seeking to protect proprietary methods at the center of its work.
The players
Colossal Biosciences
Colossal Biosciences is a Dallas-based biotechnology company launched in 2021 by Ben Lamm and George Church that pursues de-extinction projects and has drawn wide attention for its dire wolf claims.
James Kehler
James Kehler is a former senior Colossal executive and co-founder of Felix Pets who previously worked on the company's de-extinction and allergen-free cat research.
Neion Bio
Neion Bio is a start-up that manufactures medicines in chicken eggs and recently hired Kehler.
The details
Colossal alleges Kehler, a senior executive involved in its efforts to bring back the moa and dodo and its research on allergen-free cats, transferred confidential information from his company laptop to a personal cloud account and personal devices. Kehler is also a co-founder of Felix Pets, which is developing gene-edited cats for people with allergies.
Timeline
• January 2025: Colossal was valued at $10.2bn in a funding round led by TWG Global.
• April 2025: Colossal claimed it restored the dire wolf by editing the grey wolf genome and delivering pups from surrogate dogs.
• April 2026: Kehler joined Neion Bio.
• Friday: Colossal filed the lawsuit in US federal court in Texas.
The Tech Race
Colossal's April 2025 claim to have restored the dire wolf by editing the grey wolf genome set the company apart in the emerging de-extinction field. This lawsuit shows how competition for specialized biotech talent is now colliding with protection of the proprietary methods behind that technology.
The dispute centers on methods that could shape future products, including allergen-free pets that Felix Pets plans to offer. Consumers watching the sector may see how trade secret outcomes affect the timing and availability of gene-edited products.
The takeaway
Trade secret disputes can shape which companies bring new biotech products to market and when. Readers following gene-editing news can watch how courts treat claims involving talent moving between competing ventures.
Further reading
Explore more Biotech coverage for context on the gene-editing and de-extinction industry.
